Tumor News and Research

RSS

CTDNEP1 identified as potential tumor suppressor in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct.

15 Jan 2026

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ADC Manufacturing for Next-Gen Oncology, reveals an advancement in antibody-drug conjugate (ADC) manufacturing

From BioDlink 15 Jan 2026

Study highlights potential of ferroptosis-based approaches to treat cancer

Therapies that target the utilization of fat by tumors and activate a type of cell death dependent on fat molecules may be a promising avenue to treat cancer, according to new research by UTHealth Houston.

14 Jan 2026

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.

14 Jan 2026

Novel liquid biopsy technology could advance cancer diagnostics and monitoring

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow.

14 Jan 2026

Bacterial toxin shrinks tumors, enhances immune response in colorectal cancer study

A toxin secreted by cholera bacteria can inhibit the growth of colorectal cancer without causing any measurable damage to the body. This is shown by a new study by researchers at Umeå University, Sweden.

14 Jan 2026

DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.

14 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026

Novel immunotherapy targeting pancreatic cancer shows promising results in phase 1/2 trial

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial.

13 Jan 2026

Study identifies PUF60 as a critical vulnerability in triple negative breast cancer

Researchers at University of California San Diego have identified a previously unrecognized treatment target for triple‑negative breast cancer (TNBC), the most aggressive subtype of breast cancer.

12 Jan 2026

Digital twin technology guides personalized treatment for brain cancer patients

A new machine-learning-based approach to mapping real-time tumor metabolism in brain cancer patients, developed at the University of Michigan, could help doctors discover which treatment strategies are most likely to be effective against individual cases of glioma.

12 Jan 2026

Resistance to rezatapopt: New TP53 mutations identified in cancer patients

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics.

12 Jan 2026

DNA analysis of colorectal polyps improves diagnosis and treatment

In about 5–10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.

12 Jan 2026

Whole-genome sequencing improves PARP inhibitor treatment prediction

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

12 Jan 2026

Personalized cancer therapy significantly enhances treatment success

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based on the unique DNA of a patient's tumor.

12 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From Collaborative Drug Discovery, Inc. 10 Jan 2026

Ultrasound-responsive nanocatchers enable precise in-situ tumor antigen capture

Professor Zhaohui Tang and Associate Professor Zhilin Liu from the team of Professor Xuesi Chen at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed ultrasound-responsive in-situ antigen nanocatchers (S-nanocatchers), achieving precise spatiotemporal capture of tumor antigens and controllable acquisition of in-situ vaccines.

9 Jan 2026

Single-cell analysis illuminates myeloma immune landscape

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable.

9 Jan 2026

Self-administered injectable contraceptives face provider hesitancy despite availability

Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new study has found only about a quarter of reproductive health experts prescribe it - and many are unaware it's even an option.

9 Jan 2026

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure.

9 Jan 2026

Previous
1
...
46
47
48
49
50
51
52
...
1367
Next

Tumor News and Research

CTDNEP1 identified as potential tumor suppressor in pancreatic ductal adenocarcinoma

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

Study highlights potential of ferroptosis-based approaches to treat cancer

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

Novel liquid biopsy technology could advance cancer diagnostics and monitoring

Bacterial toxin shrinks tumors, enhances immune response in colorectal cancer study

DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer

Preclinical study reveals potential new treatment for severe liver fibrosis

Novel immunotherapy targeting pancreatic cancer shows promising results in phase 1/2 trial

Study identifies PUF60 as a critical vulnerability in triple negative breast cancer

Digital twin technology guides personalized treatment for brain cancer patients

Resistance to rezatapopt: New TP53 mutations identified in cancer patients

DNA analysis of colorectal polyps improves diagnosis and treatment

Whole-genome sequencing improves PARP inhibitor treatment prediction

Personalized cancer therapy significantly enhances treatment success

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Ultrasound-responsive nanocatchers enable precise in-situ tumor antigen capture

Single-cell analysis illuminates myeloma immune landscape

Self-administered injectable contraceptives face provider hesitancy despite availability

Immune cell atlas may improve survival predictions, guide treatment decisions in multiple myeloma

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News